← Leaderboards
Joseph Largay
University Of North Carolina Chapel Hill
$0
Attributed
$0
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 3
By mechanism
M01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- John B Buse$71,388,050
- Rosalind A. Coleman$12,612,555
- Gerardo Heiss$39,428,129
- Patrick H Nachman$4,212,672
- Alan L Hinderliter$1,352,339
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNoninsulin Dependent Diabetes MellitusHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationDiabetes Mellitus TherapyDosageDrug Administration RoutesHormone TherapyAntiatherogenic AgentAtherosclerosisBlood GlucoseChemopreventionComorbidityCoronary DisorderIncretin HormoneLow Density LipoproteinPlacebosClinical Trial Phase ISulfonylureaGlyburideExerciseHypoglycemic Agents
Grant awards (7)
ATORVASTATIN AS PREVENTION OF CHD IN PTS W/ NIDDM$0
M01 · FY2000 · RR
ATORVASTATIN AS PREVENTION OF CHD IN PTS W/ NIDDM$0
M01 · FY2000 · RR
ATORVASTATIN AS PREVENTION OF CHD IN PTS W/ NIDDM$0
M01 · FY2000 · RR
REPAGLINIDE VS SULFONYLUREAS ON EXERCISE INDUCED HYPOGLYCEMIA$0
M01 · FY2000 · RR
EFFECTS OF SUBCUTANEOUS ADMINISTRATED AC2993 IN NIDDM$0
M01 · FY2000 · RR
EFFECTS OF SUBCUTANEOUS ADMINISTRATED AC2993 IN NIDDM$0
M01 · FY2000 · RR
EFFECTS OF SUBCUTANEOUS ADMINISTRATED AC2993 IN NIDDM$0
M01 · FY2000 · RR